Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MTATP6P13, also referred to as mitochondrially encoded ATP synthase 6 pseudogene 13, is a human mitochondrial DNA pseudogene closely related to the functional MT-ATP6 gene[1][2][3]. While MT-ATP6 encodes a subunit of the F-type ATP synthase (complex V), essential for mitochondrial ATP synthesis and implicated in mitochondrial disorders like Leigh syndrome and NARP[1][2][3][5][6], MTATP6P13 itself is a non-functional gene segment that does not encode any protein and has no known biological or disease function. It is cataloged in sequence databases for genomic annotation and evolutionary study, but is not considered a therapeutic target, receptor, enzyme, or druggable entity. Summary distinction: If you seek information on the enzyme or disease associations, refer to MT-ATP6 (mitochondrially encoded ATP synthase membrane subunit 6), not the pseudogene MTATP6P13[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrially encoded ATP synthase 6 pseudogene 13 (MTATP6P13).